COVID-19患者恢复期血浆在COVID-19治疗中的应用

Application of convalescent plasma from patients with COVID-19 in treatment of Coronavirus Disease 2019

2020年新型冠状病毒肺炎(COVID-19)大流行给全球的公共卫生提出巨大挑战,目前暂无特异性抗病毒药物,COVID-19康复者提取的恢复期血浆(convalescent plasma,CP)被认为是治疗重症急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)感染最为及时有效的特异性生物疗法之一。研究证明,含有高滴度SARS-CoV-2中和抗体的CP安全性良好,可有效阻断病毒复制,改善患者临床症状。本文简要综述了CP在COVID-19治疗中的应用,探讨了其作用机制、相关临床研究以及可能影响临床效果的因素,以期有助于CP在治疗COVID-19中的合理应用。

The pandemic of Coronavirus Disease 2019(COVID-19)in 2020 has posed a great challenge to global public health resources. Since there are no specific antiviral drugs at present,convalescent plasma(CP)from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection. Preliminary studies have shown that the CP containing high titer neutralizing antibody against SARS-CoV-2 is safe and promising in blocking viral replication and improving patients′clinical symptoms. In this article,we briefly summarize the application of CP in treatment of COVID-19,and explores possible action mechanism,relevant clinical research and possible influencing factors of clinical effect,which may be helpful to the rational application of CP in treatment of COVID-19.